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Background: Autism spectrum disorder (ASD) is a highly heritable, neurodevelopmental condition showing
extreme genetic heterogeneity. While it is well established that rare genetic variation, both de novo and inherited,
plays an important role in ASD risk, recent studies also support a rare recessive contribution.
Methods: We identified a compound heterozygous deletion intersecting the CTNNA3 gene, encoding αT-catenin,
in a proband with ASD and moderate intellectual disability. The deletion breakpoints were mapped at base-pair
resolution, and segregation analysis was performed. We compared the frequency of CTNNA3 exonic deletions in
2,147 ASD cases from the Autism Genome Project (AGP) study versus the frequency in 6,639 controls. Western blot
analysis was performed to get a quantitative characterisation of Ctnna3 expression during early brain development
in mouse.
Results: The CTNNA3 compound heterozygous deletion includes a coding exon, leading to a putative frameshift
and premature stop codon. Segregation analysis in the family showed that the unaffected sister is heterozygote for
the deletion, having only inherited the paternal deletion. While the frequency of CTNNA3 exonic deletions is not
significantly different between ASD cases and controls, no homozygous or compound heterozygous exonic
deletions were found in a sample of over 6,000 controls. Expression analysis of Ctnna3 in the mouse cortex and
hippocampus (P0-P90) provided support for its role in the early stage of brain development.
Conclusion: The finding of a rare compound heterozygous CTNNA3 exonic deletion segregating with ASD, the
absence of CTNNA3 homozygous exonic deletions in controls and the high expression of Ctnna3 in both brain
areas analysed implicate CTNNA3 in ASD susceptibility.
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variantsBackground
Autism spectrum disorder (ASD) is a group of related life-
long neurodevelopmental conditions that affect about 1 in
110 individuals [1]. ASD is characterised by defects in
communication, impaired reciprocal social interaction,
repetitive behaviours and restricted interests, with onset
before age 3 years. A peculiarity of ASD is a gender bias,* Correspondence: elena.maestrini@unibo.it
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unless otherwise stated.with males having a greater than threefold higher risk for
ASD as compared to females [2].
Despite the high heritability of ASD (approximately
90%), its basis remains poorly explained by common
genetic risk variants [3]. Genome-wide association stu-
dies (GWAS) have so far provided only tenuous evi-
dence for individual common variants that affect risk of
ASD [3-6], drawing attention to the contribution of rare
variants to ASD pathophysiology. Indeed, recent studies
have shown that rare genomic variation, both copy num-
ber variants (CNVs) and point mutations, may account
for a significant proportion of cases of idiopathic autismal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that some 10% of ASD subjects carry a de novo risk va-
riant, demonstrating that de novo genetic variation has an
important role in risk for an ASD phenotype, this me-
chanism is inconsistent with the widely recognized high
heritability. Convincing statistical evidence for the role of
rare recessive inherited variants in ASD risk comes from
two recent studies that applied whole-exome sequencing
to a cohort of consanguineous and/or multiplex families
and to ASD cases using a population-based approach
[8,9]. The contribution of recessive mutations to ASD her-
itability is supported by the success of homozygosity map-
ping to identify autism genes in consanguineous families
[10], the use of homozygosity mapping as a powerful stra-
tegy for filtering whole-exome sequence data [11] and the
identification that ASD probands display a much higher
degree of haplotype sharing within overlapping homozy-
gous regions compared to parental controls [12].
In the second stage of the Autism Genome Project
(AGP) genome-wide study, amounting to approximately
1,600 ASD families [13], we detected one rare compound
heterozygous deletion involving the CTNNA3 gene, en-
coding αT-catenin, in a proband with autism. CTNNA3 is
a member of the α-catenin family and has a crucial role in
cell adhesion, one of the major pathways implicated in
ASD [4,14-17]. CTNNA3 has been implicated as a possible
autism candidate gene (https://gene.sfari.org/GeneDetail/
CTNNA3#HG). Previous studies reported common single
nucleotide polymorphism (SNP) association [4,5] and the
occurrence of rare CNVs intersecting CTNNA3 in ASD
cases [18-21]. Therefore, the recessive inheritance pattern
seen in this family leads us to hypothesize that total loss of
CTNNA3 may cause the ASD phenotype.
In this study, we genetically characterised the rare
CTNNA3 compound heterozygous microdeletion, per-
formed segregation analysis and further clinical evaluation
in this nuclear family, assessed the rate of CTNNA3 dele-
tions in ASD cases and controls and assessed the protein
expression pattern of CTNNA3 in the developing mouse
brain. This is the first report of a compound heterozygous
exonic deletion in CTNNA3.
Methods
Characterisation and segregation analysis of CTNNA3
deletions
The maternal and the paternal exon 11 CTNNA3 micro-
deletions segregating in family 3456 were amplified via
several polymerase chain reaction (PCR) assays using the
Gold Taq polymerase (Life Technologies, Carlsbad, CA,
USA). Primer pairs were designed following visual inspec-
tion of the Illumina 1 M-duo SNP array data from the
second stage of the AGP genome-wide CNV study [13],
within GenomeStudio (Illumina, San Diego, CA, USA).
The paternal 301-bp and the maternal 949-bp deletion-spanning amplicons were purified using Exosap (GE
Healthcare, Little Chalfont, UK) and then sequenced using
BigDye Terminator kit v1.1 (Life Technologies) to deter-
mine the exact boundaries of the deletions. An additional
primer pair that amplifies exon 11 of CTNNA3 (not-
deleted allele) was subsequently used to confirm that the
identified deletions in family 3456 were in the heterozy-
gous or homozygous status.
The experimental validation of CTNNA3 exonic dele-
tions in four other ASD families was carried out by real-
time quantitative PCR (qPCR) using Fast SYBR Green
(Life Technologies). Each assay was conducted in tripli-
cate, with at least three sets of primers corresponding to
the region of interest and another mapping to a control
region on FOXP2 gene at 7q31.1. The number of copies of
each amplified fragment was calculated using the ΔΔCt
method [22]. The parents and additional affected or un-
affected siblings were also tested for inheritance and seg-
regation of CNVs, respectively.
All primer sequences and conditions used for ampli-
fication, Sanger sequencing and qPCR are available on
request.
Numbering for CTNNA3 exons is based on the Reference
Sequence (RefSeq) NM_013266.
Population analysis of CTNNA3 exonic deletion
The ASD samples used here were collected as part of
the Autism Genome Project. All diagnostic, clinical and
cognitive assessments of these samples were previously
described [13,23].
CTNNA3 exonic deletions in ASD samples were iden-
tified as a part of the AGP study [13,23]. Briefly, all
CTNNA3 exonic deletions reported in ASD samples are
high-confidence CNVs predicted by intersecting CNV calls
from at least two algorithms between iPattern, PennCNV
and QuantiSNP. This strategy ensures maximum specifi-
city because each of these algorithms employs unique
strategies for CNV calling, allowing their strengths to be
leveraged. Previous analysis showed that validation rates
were approximately 95% for CNVs identified using this
method [23].
Control cohort microarray data include 1,287 unrelated
European control subjects from the Study of Addiction:
Genetics and Environment cohort (SAGE) [24] genotyped
with Illumina Human 1 M-single BeadChip arrays, 1,123
Northern Europeans from the German PopGen project
(POPGEN) [25] genotyped on the Affymetrix 6.0 SNP
array (Affymetrix, Santa Clara, CA, USA), 1,234 indi-
viduals of European decent from the Ottawa River Valley
(OHI) [26] genotyped on the Affymetrix 6.0 SNP array,
1,320 European control subjects routinely seen at primary
care and well-child clinic practices within the Children's
Hospital of Philadelphia (CHOP) Health Care [27] geno-
typed with Illumina 550 K BeadChip, 435 unrelated
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Cancer Case-Control study (OC) [28] genotyped with the
Illumina 1 M single array and 1,240 European controls
from the NHGR-CIDR Visceral Adiposity Study [29] ge-
notyped on Illumina 1 M-duo BeadChip arrays. For all
these control samples (except for the CHOP samples, for
which the CNV data are available at http://cnv.chop.edu),
the heterozygous state of exonic CTNNA3 deletions has
been determined by inspecting the genotypes and/or plot-
ting B allele freq and log R ratios for each region.
Statistical comparison of CTNNA3 exonic deletion fre-
quencies between ASD cases and controls was per-
formed using Fisher's exact test.
All data from either patients or their caretakers and
controls, including the informed consent, were handled
in accordance with the local ethical committee's ap-
proved protocols and in compliance with the Helsinki
declaration.
CTNNA3 and LRRTM3 exon sequencing
All coding exons, intron-exon boundaries and the 5′-UTR
of CTNNA3 and the nested gene LRRTM3 have been amp-
lified by PCR in all members of four families carrying
CTNNA3 exonic deletions. Primer sequences and PCR con-
ditions used for amplification (20 amplicons for CTNNA3
and 5 amplicons for LRRTM3) are available on request.
PCR products were purified using Exosap (GE Healthcare)
and then sequenced using BigDye v1.1 (Life Technologies).
Human brain samples
Human brain samples from the frontal cerebral cortex
and cerebellum were obtained from deep frozen (−80°C)
slices of two adult control subjects. Written informed con-
sent for research use, given by the patients during life or
by their next of kin after death, was available for all human
brain tissues used for RNA analyses.
RT-PCR
Total RNA from human frozen brain tissues (30–40 mg)
was extracted using the Qiagen Total RNA kit (Qiagen,
Venlo, the Netherlands), and reverse transcriptase PCR
(RT-PCR) was performed using the Superscript III First
Strand Synthesis SuperMix (Life Technologies) accor-
ding to the manufacturer's protocol. Two microlitres
of complementary DNA (cDNA) was used for testing
CTNNA3 expression in the human frontal cerebral cortex
and cerebellum using a forward primer designed in exon
10 (CCAATCATTTGGAAACCTTGTG) and a reverse
primer mapping in exon 15 (CTCAATCTCAGCATC
CAGCTTA), in order to amplify a cDNA fragment in-
cluding the coding SNP rs4548513 (pSer596Asn). PCR
products were purified and sequenced as described before
using primers GTTACGAGCCAGGGGCTTAC and CAA
GGTCAGAAACATCCTCCA.Western blot analysis
The hippocampus and cortex were dissected from three
animals (C57Bl/6 N) at each time point pooled together.
Samples were lysed with lysis buffer containing 1% SDS
and boiled. Forty micrograms of total proteins were loaded
onto a 4%–12% polyacrylamide gel (Life Technologies) and
then transferred to a nitrocellulose membrane (Whatman).
Filters were hybridized with antibodies against N-catenin
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or
T-catenin [30] or GAPDH (Millipore, Billerica, MA, USA)
as housekeeping control and then revealed by using
HRP-conjugated specific secondary antibodies (BioRad,
Hercules, CA, USA) and ECL (GE Healthcare). ImageJ was
used to quantify bands.
Experiments were done according to the animal proto-
cols approved by the Institutional Animal Care and Use
Committee San Raffaele (IACUC) (San Raffaele, Milan,
Italy) and were approved by the National Ministry of
Health, IACUC ID 470. All experiments were carried
out in accordance with the guidelines established by the
European Community Council Directive of 24 November
1986 on the use of animals in research (86/609/EEC). All
efforts were made to minimize animal suffering and to use
only the number of animals necessary to produce reliable
results.
Results
Clinical assessment of family 3456
The propositus was the first child of healthy non-consan-
guineous parents, born at 39 weeks gestation by sponta-
neous delivery. During pregnancy, there was no exposure
or history of chronic illnesses, alcohol, tobacco or street
drugs. Family history was non-contributory. Birth weight
was 3,500 g (50th centile), length 52 cm (90th centile) and
occipitofrontal circumference (OFC) 34.5 cm (50th cen-
tile). Apgar was 8–9. He was breast fed with good suction.
He sat unsupported at 9 months and walked alone at
19 months. He babbled at 12 months and was able to pro-
nounce his first words at 30 months. Echolalia was noted.
Sleep-wake rhythm was normal. Feeding was selective for
semi-solid foods. He was withdrawn from early on. He
showed no interest toward his peers and was very passive,
with no eye-to-eye contact. His behaviour was charac-
terised by motor instability, low level of frustration toler-
ance, very poor and repetitive interests, bruxism and, on
occasion, motor stereotypies. Metabolic work-up, brain
MRI, BAEP and EEG were reportedly normal.
We first saw him at age 4 years 8 months. On exami-
nation, there were bilateral epicanthal folds, large and
anteverted ears, high arched palate and bilateral pes pla-
nus pronatus. Height was 113.5 cm (90th centile), weight
17.5 kg (50th centile) and OFC 50 cm (2nd to 50th
centile). Neurological examination showed mild joint
laxity. Language was limited to simple sentences, with
Figure 1 (See legend on next page.)
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Figure 1 Detection and breakpoint definition of CTNNA3 deletions in the discovery pedigree. (A, C) Sequence electropherograms with
breakpoint-spanning sequences in the mother and in the father, respectively (NCBI build 36 coordinates). In (A) the two base pairs (AT), common
to both ends, are highlighted in blue. (B) GenomeStudio plots of the log R ratio and B allele frequency data from the 1 M-Duo SNP array for
family 3456. The deletions result in a decrease in the log R ratio and a lack of heterozygous variants (the expected allelic ratio for heterozygous
variants is 0.5). The deleted SNPs are depicted in red, and the red rectangle indicates the region deleted on both alleles in the proband.
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was contextual.
When last seen, aged 5 years 6 months, height was
118 cm (90th centile), weight 22 kg (75th to 90th centile)
and OFC 50.5 cm (2nd to 50th centile). He had a border-
line cognitive impairment (Griffiths Mental Developmen-
tal Scales and Leiter International Performance Scale),
with performance better than verbal competences. At the
ADOS-G and ADI-R, he met criteria for autism on both
instruments. At age 5 years, he was started on risperidone.
Molecular analysis at the FRAXA/E loci was normal.
His younger sister has normal cognition (WISC-R:
TIQ 86; VIQ 90; PIQ 85) with normal social and com-
munication skills. Both parents, heterozygotes for the
deletion, do not show any evident cognitive or beha-
vioural impairment.
Fine-mapping and segregation analysis of CTNNA3
deletion in family 3456
During the second stage of a large genome-wide scan for
CNVs carried out by the AGP, we detected an exonic dele-
tion in the CTNNA3 gene inherited from both parents,
each heterozygote for a deletion of slightly different length.
After manual inspection of the log R ratios and B allele
frequencies in GenomeStudio, the minimal deleted region
was determined to be from rs12254628 to rs7919336 in
the mother 3456_2 and from rs4587626 to rs7077638 in
the father 3456_1 (Figure 1B). Using several PCR assays
with primers designed to flank the predicted breakpoints,
we defined and sequenced the breakpoints of the two
slightly different microdeletions carried by the parents of
family 3456: the maternal microdeletion encompassed
chr10: 67,942,931–68,002,674, while the paternal one
spanned chr10: 67,898,172–67,997,846 (National Center for
Biotechnology Information build 36 coordinates) (Figure 1A
and C).
Since the maternal and paternal deletions have different
breakpoints, they cannot be due to a single ancestral
event. Sequencing of the deletion breakpoints showed the
presence of 2–5-bp microhomology at the junctions of the
maternal and paternal deletions, respectively (Additional
file 1: Figure S1) as well as the insertion of a 26-bp A-T
rich sequence at the paternal deletion junction. These ob-
servations, together with the non-recurrent nature of the
deletions and the absence of flanking low copy repeats(LCR), suggest that these deletions are likely to be gener-
ated through a microhomology-mediated repair mechan-
ism [31].
The same PCR assays were also used to analyse the
segregation of the two microdeletions in the family: while
the ASD proband inherited both microdeletions, the un-
affected sister inherited only the paternal microdeletion
(Figure 2A,B). Both deletions remove exon 11 of CTNNA3
(Figure 2C): exon 11 is present in both the full-length
CTNNA3 isoforms a (NM_013266 and NM_001127384),
which are two transcript variants that differ only for the
first 5′ non-coding exon. CTNNA3 transcripts missing
exon 11 are predicted to result in a frameshift, with the
introduction of 12 novel amino acids followed by a pre-
mature termination codon but also probably inducing
nonsense-mediated decay. However, CTNNA3 was un-
detectable in blood RNA by RT-PCR, so it was not pos-
sible to confirm the functional effect of this exonic
deletion.
CTNNA3 exonic deletion frequency in ASD cases and
controls
Given the discovery of a compound heterozygous deletion
of exon 11 in CTNNA3 in a male proband with autism, we
examined the frequency of CTNNA3 exonic deletions in
autism and control populations. To address this issue, we
used the existing CNV data on a total of 2,147 European
ASD families from the recent AGP genome-wide study
(combined sample of stage 1 and stage 2 families) [13] and
CNV data on 6,639 European controls [24-29].
We identified a total of 14 additional heterozygous exonic
deletions in ASD probands (allelic frequency = 0.37%), thus
showing a modest deviation from the Hardy-Weinberg
equilibrium (exact test P = 0.028). In the control population,
we found 43 CTNNA3 exonic deletions (allelic frequency
0.32%), indicating a comparable frequency between ASD
cases and controls (Table 1, P = 0.62). Parental information
was available for 13 out of 15 ASD families, and in none of
these cases, CTNNA3 exonic microdeletions were de novo.
The observed exonic deletions are different in position, size,
sequence junctions and genomic content, removing one or
two exons, spanning from exon 6 to exon 13 of CTNNA3
(Additional file 2: Table S1). This is in accordance with
CTNNA3 being located in a common fragile site [32], a re-
gion characterised by increased genomic instability [33].
Figure 2 Further characterisation of CTNNA3 deletions in the pedigree 3456. (A) From the left, results of PCR across father's and mother's
deletion breakpoints, respectively: only the allele with the deletion can be amplified and visualized as a band of 301 bp in the father, in the proband
and the unaffected sister, and as a band of 949 bp in the mother and in the proband. On the right, the amplification with primers mapping in the
deleted exon of CTNNA3 indicates the presence of at least one allele without the deletion. At both extremities of the gel, 1-kb Plus and 100-bp DNA
ladder were loaded. (B) The segregation pattern for these two deletions involving CTNNA3 in the discovery pedigree. Autism is indicated in black filling.
(C) Schematic from the UCSC genome browser. The figure shows the position of the two CTNNA3 deletions in the pedigree 3456. The region shown
corresponds to approximately 1.8 Mb on 10q21.3 (NCBI build 37 coordinates).
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biguous loss-of-function alleles, we focused our attention
to this class of deletions. Among the observed exonic
CTNNA3 deletions in case and controls (Additional file 2:
Table S1), only deletions that remove exon 7, exons
10–11, exon 11 and exon 13 (NM_013266) are predicted
to induce frameshifts, but their frequency is not sig-
nificantly different between cases and controls (Table 1,
P = 0.56).
Segregation analysis of CTNNA3 exonic deletions and
mutation screening of CTNNA3 and LRRTM3 in four ASD
families with affected and/or unaffected siblings
To investigate if CTNNA3 exonic deletions segregate
with the ASD phenotype, we screened the affected and
unaffected siblings in three multiplex families and one







ASD cases 2,147 16b 0.37
Controls 6,639 43 0.32
aFisher's exact test; bIncluding the two exon 11 deletions in family 3456.deletions by qPCR. All CTNNA3 deletions segregate
with ASD phenotype within the family, except for the
exon 13 deletion in family 3311 that is transmitted from
the mother to only two out of three affected children
(Figure 3).
In the hypothesis that the CTNNA3 deletions could
act by unmasking rare variants in the non-deleted allele,
we sequenced the entire coding sequence of CTNNA3
and of the nested gene LRRTM3 (leucine-rich repeat
transmembrane neuronal 3) in all family members of the
same four ASD families carrying heterozygous exonic
deletions. Sequence analysis did not detect any novel
exonic variants in CTNNA3, while a previously unde-
scribed missense change (pArg275Ser) was identified in
LRRTM3 in family 3476; however, this missense variant
was transmitted from the unaffected father, who also






0.62 6b 0.14 0.56
14 0.11
Figure 3 Pedigree of four ASD families carrying CTNNA3 exonic deletions. Black filling indicates ASD diagnosis.
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both the CTNNA3 deletion and the LRRTM3 missense
variant are present in the unaffected father.
CTNNA3 expression analysis
We were unable to obtain a reliable amplification of
CTNNA3 and LRRTM3 transcripts using RT-PCR in
blood RNA or Epstein Barr virus (EBV)-transformed cell
lines, in accordance with their previously described re-
stricted expression pattern [30]. Therefore, it was not
possible to test the functional effect of the heterozygous
and homozygous loss of exon 11 in family 3456.
It has been previously reported that CTNNA3 is sub-
ject to genomic imprinting, with preferential monoallelic
expression of the maternal allele in placental tissue [34].
Here we investigated the allelic expression of rs4548513,
a CTNNA3 exon 13 coding SNP (pSer596Asn), in the
cerebellum and cerebral cortex of two informative he-
terozygous adult controls. RT-PCR analysis showed high
expression levels in the cerebellum and cerebral cortex,
and Sanger sequencing of the PCR products showed
biallelic expression of CTNNA3 in both brain areas
(Additional file 3: Figure S2).
Since the mouse Ctnna3 cDNA encodes a protein
showing 95% identity to human CTNNA3 and the
genomic structures of the mouse Ctnna3 and human
CTNNA3 genes are completely conserved, we have per-
formed a Western blot analysis to get a quantitative
characterisation of Ctnna3 expression during early brain
mouse development compared with the neural specific
Ctnna2.
Protein extracts of mouse cortex and hippocampus at
different developmental stages (from P0 to P90) wereprobed with anti-N-catenin antibody that recognizes
specifically the C-terminus of Ctnna2 as a doublet band
and a rabbit polyclonal anti-αT-catenin antibody (#952),
which recognizes a specific peptide corresponding to the
C-terminus of Ctnna3. As shown in Figure 4, not only
Ctnna2 is highly expressed at all brain developmental
stages analysed, but also Ctnna3 is present in both brain
areas analysed. Noticeably, Ctnna3 showed a higher
expression in the hippocampus and cortex at P0, sug-
gesting a specific neuronal role in very early develop-
mental stages.
Discussion
In a recent genome-wide scan performed by the AGP in
the largest family-based sample of ASD reported to date
[13], we have identified a compound heterozygous
deletion encompassing the CTNNA3 gene in a male pro-
band with autism. This deletion removes a coding exon
(exon11), leading to a putative frameshift and premature
stop codon, and it is inherited from both parents, each
heterozygote for a deletion of slightly different length.
Given the likelihood of nonsense-mediated mRNA decay
of CTNNA3 transcripts carrying exon 11 deletions, this
compound heterozygous deletion is thus expected to
result in a complete lack of functional protein in the
affected individual.
This discovery is of particular interest as CTNNA3 is a
very promising candidate gene for ASD based on its bio-
logical function, such as its crucial role in cell adhesion,
a pathway previously implicated in ASD. CTNNA3
encodes αT-catenin, a member of the α-catenin family
of cell-cell adhesion molecules. Like other α-catenins,
CTNNA3 provides an indispensable link between the
Figure 4 Expression analysis of ctnna3 in mouse brain. Western blot analysis of αT-catenin and αN-catenin in mouse hippocampus (A) and
cortex (B) at different developmental stages (from P0 to P90). (C, D) Histograms showing the band intensity normalised by GAPDH as internal
loading control.
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skeleton to mediate cell-cell adhesion.
There are three alpha catenin genes: CTNNA1 (alpha
E-catenin) is ubiquitously expressed but mainly in epi-
thelial tissues [35], CTNNA2 (alpha N-catenin) shows a
neural specific expression pattern [36], and CTNNA3
(alpha T-catenin) is expressed primarily in the heart and
testis but at lower levels in the brain [30].
The role of CTNNA3 has been primarily investigated
in the heart, due to its high expression in cardiac tissue
and co-localization with plakophilin 2 [37]. Furthermore,
genetic linkage and association studies have indicated
that the CTNNA3/LRRTM3 locus may play a role in
susceptibility to late-onset Alzheimer's disease and plas-
ma amyloid β levels [38-40]. However, the function of
CTNNA3 in the brain remains largely unexplored.
Our Western blot characterisation of mouse Ctnna3
expression showed that it displays higher expression in
the hippocampus and cortex at P0, suggesting a specific
neuronal role in very early developmental stages. Thus,
further studies are warranted in order to investigate the
possible function of CTNNA3 in synapse adhesion [41].
It has been shown that Ctnna2 functions as a critical
agent to regulate the stability and remodelling of synap-
tic contacts, as its loss causes deformation of dendritic
spines, while its overexpression in dendrites causes an
increase in spine and synapse density [42]. Overexpres-
sion of Ctnna3 and Ctnna1 also induced excess spine
formation, suggesting that all α-catenin isoforms share
the same spine-stabilizing activity [42]. Moreover, like
other α-catenins, Ctnna3 participates in the canonical
Wnt signalling pathway [43], which plays an important
role in brain development and synaptic function. CNVand association studies investigating several genes in-
volved in this pathway have provided evidence that Wnt
signalling might be affected at least in a subset of indi-
viduals with ASD [44].
Beyond its biological plausibility, evidence for a poten-
tial role of CTNNA3 in ASD susceptibility comes also
from genetic studies. Two genome-wide association stu-
dies implicated common variants in CTNNA3 in autism
susceptibility [4,5]. Another study reported a de novo
exonic deletion in CTNNA3 associated to ASD, with ad-
ditional evidence from transmission data [18]. Moreover,
in a recent analysis of exon-disrupting CNVs affecting
known autism candidate genes, CTNNA3 was found bor-
derline enriched in the autism cohort as opposed to con-
trols (22 out of 2,588 autism cases versus 12 out of 2,670
controls, P = 0.050) [21]. Even if we have not confirmed
this trend of enrichment for CTNNA3 exonic deletions
among children with ASD, no homozygous or compound
heterozygous exonic deletions were found in a sample of
6,639 controls, suggesting that CTNNA3 is haplosufficient
and that only a recessive loss of function may play a role
in ASD susceptibility. This hypothesis is consistent with
the segregation of CTNNA3 deletions in the discovery
family 3456, as the unaffected sister inherited the exonic
deletion in the heterozygous form. By sequence analysis of
coding region of CTNNA3 and the nested gene LRRTM3
in four ASD families carrying exonic CTNNA3 deletions,
we could not confirm that these deletions act by unmas-
king rare variants in the non-deleted allele; however, we
cannot exclude the possibility of point mutations in non-
coding regions disrupting gene regulation or splicing.
Evidence of recessive inheritance in ASD comes from
a study of consanguineous and multiplex ASD families
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which estimated an overall 3% contribution to risk for
ASD from recessive mutations. The proposed role of re-
cessive mutations in ASD is also in accordance with the
high heritability of ASD [45] and with the observation
that the majority of parents of ASD individuals are both
unaffected.
Notably, CTNNA3, one of the largest genes in the
human genome, is located in a common fragile site
(FRA10D) [32]. Increasing evidence links multiple fragile
sites, which are considered hot spots for genomic instabi-
lity, to neuropsychiatric diseases including autism [46,47].
Another feature that makes CTNNA3 particularly inter-
esting is the presence of a nested gene (LRTMM3), tran-
scribed in the opposite direction. Interestingly, all three
members of the alpha catenin family harbour leucine-rich
repeat transmembrane neuronal (LRRTM) genes nested
within the largest intron of each catenin family member.
This structure is likely to derive from the insertion of an
ancestral lrrtm gene into a pre-existing ctnna intron dur-
ing early vertebrate evolution, followed by two subsequent
duplications resulting in the three nested lrrtm/ctnna
genes [48]. The LRRTM family members are brain-
enriched transmembrane proteins, proposed to function
as synaptic organizers during synapse development [49]
by interacting with presynaptic neurexins [50]. LRRTM3
displays expression predominantly in the brain, notably in
the hippocampus, and, similar to CTNNA3, is thought to
mediate cell adhesion [51,52]. The location of three
LRRTM genes within α-catenin family members implies
that transcriptional regulation of α-catenin genes and the
respective LRRTMs could share common mechanisms.
Therefore, it is plausible to hypothesize that deletions in
CTNNA3 could cause dysregulation of LRRTM3 expres-
sion. However, given the CNS-restricted expression of
LRRTM3, it was not possible to test this hypothesis in the
patient's lymphocytes. Interestingly, a significant asso-
ciation of SNPs in LRRTM3 with ASD in European
populations was reported in a previous study [53], thus
accumulating evidence that genetic variants in the
CTNNA3/LRRTM3 genomic region confer susceptibility
to ASD.
Recently, gene targeting technology was used to delete
the Ctnna3 gene in the mouse to investigate the role of
Ctnna3 in the heart where it is highly expressed. The
Ctnna3-null mice are viable and fertile and show no ob-
vious macroscopic phenotypic abnormality; however, they
exhibit early-onset progressive dilated cardiomyopathy,
gap junction remodelling and increased risk of cardiac
arrhythmia [54]. To our knowledge, a detailed cognitive
and behavioural characterisation of the Ctnna3-null
mouse has not yet been carried out, which could provide
important information about the presence of subtle im-
pairments in behavioural assays relevant to the complexbehaviours involved in autism [55]. In contrast to the
mouse knock-out phenotype, when last evaluated, the
child 3456_3 with the compound heterozygous CTNNA3
deletion had a normal EKG and heart ultrasound. This
suggests that CTNNA3 deficiency does not lead to a car-
diac dysfunction in humans.
Conclusions
Given the crucial role of catenins in both the development
and maintenance of the nervous system, we believe that
mutations affecting α-catenin's function may contribute to
ASD pathogenesis. More specifically, our work implicates
CTNNA3 as a candidate gene in ASD, acting in a recessive
mode of inheritance, and leads us to hypothesize that the
identified compound heterozygous exonic deletion in
CTNNA3 causes ASD in family 3456. We also provide evi-
dence that heterozygous exonic deletions in CTNNA3 are
not pathological. These results may be valuable in the
context of clinical diagnosis and counselling.
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